AstraZeneca Launches Four New Collaborations to Feature CRISPR in R&D

Jan 29, 2015

|

NEW YORK (GenomeWeb) – AstraZeneca today announced four collaborations to implement CRISPR/cas9 genome editing technology across its drug discovery platform.

The firm's collaborators are the Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Thermo Fisher Scientific, and the Broad and Whitehead Institutes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Who Are You?

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

'Problematic'

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Republicans Take on Peer Review

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

This Week in Science

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

Main menu